Compare
AbbVie vs Halozyme (ABBV vs HALO)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Halozyme (HALO) +51.7%; so far this year the figures are +27.5% and +54.0%.
AbbVie is the larger company by market value, about 43.6 times the size of Halozyme.
On trailing earnings, ABBV trades at 50.1 times and HALO at 25.8 times.
Revenue grew +10.7% at ABBV and +45.0% at HALO over the last year.
ABBV yields 2.38%. HALO pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | HALO | |
|---|---|---|
| Price | $291.31 | $103.63 |
| 1-day | +1.07% | -15.72% |
| YTD | +27.49% | +53.98% |
| 1 year | +34.39% | +51.73% |
| 3 years | +104.47% | +209.25% |
| Market cap | $514.9B | $11.8B |
| P/E | 50.1 | 25.8 |
| P/S | 7.80 | 6.55 |
| P/B | — | — |
| Revenue growth | +10.70% | +45.00% |
| EPS growth | +340.20% | -15.60% |
| Gross margin % | 73.7 | 82.3 |
| Net margin % | 15.7 | 26.9 |
| ROE % | — | — |
| Debt / equity | — | — |
| FCF yield % | 3.7 | 7.5 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.59 |
| RSI (14) | 59.7 | 29.2 |
| Technical rating |